{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:40:04Z","timestamp":1752237604968,"version":"3.41.2"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/spjnwn6iresz","name":"Science and Technology Planning Project of Shenzen Municipality","doi-asserted-by":"publisher","award":["KCXFZ20230731100901003"],"award-info":[{"award-number":["KCXFZ20230731100901003"]}],"id":[{"id":"10.13039\/spjnwn6iresz","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spdkzagvmi4b","name":"Science and Technology Planning Project of Shenzen Municipality","doi-asserted-by":"publisher","award":["JCYJ20190809144005609"],"award-info":[{"award-number":["JCYJ20190809144005609"]}],"id":[{"id":"10.13039\/spdkzagvmi4b","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spcmx7prlgep","name":"Science and Technology Planning Project of Shenzen Municipality","doi-asserted-by":"publisher","award":["JCYJ20210324131212034"],"award-info":[{"award-number":["JCYJ20210324131212034"]}],"id":[{"id":"10.13039\/spcmx7prlgep","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/sphdgnsogbbw","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["22020A1515010586"],"award-info":[{"award-number":["22020A1515010586"]}],"id":[{"id":"10.13039\/sphdgnsogbbw","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spiadzo6ceis","name":"Shenzhen Third People\u2019s Hospital","doi-asserted-by":"publisher","award":["G2021014"],"award-info":[{"award-number":["G2021014"]}],"id":[{"id":"10.13039\/spiadzo6ceis","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/sppotbmfbutf","name":"Science and Technology Planning Project of Shenzen Municipality","doi-asserted-by":"publisher","award":["JCYJ20220530163406016"],"award-info":[{"award-number":["JCYJ20220530163406016"]}],"id":[{"id":"10.13039\/sppotbmfbutf","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/sp3efn6jvusm","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200148"],"award-info":[{"award-number":["32200148"]}],"id":[{"id":"10.13039\/sp3efn6jvusm","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pyrazinamide is used to treat drug-susceptible (DS) and multidrug-resistant (MDR) tuberculosis (TB). This study aimed to characterize the factors associated with the pharmacokinetic parameters of pyrazinamide and evaluate the disposition of the current regimen, which could provide suggestions for adequate dosing strategies for therapeutic targets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A population pharmacokinetic model of pyrazinamide was developed based on the data from 499 plasma concentrations from 222 Chinese patients diagnosed with DS or MDR TB. Pyrazinamide exposure was best described using a one-compartment model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>No significant differences were observed in the pharmacokinetic parameters between DS and MDR TB. The final covariate model showed that total body weight was the only significant covariate for apparent clearance, which increased by 0.45 L\/h with a 10 kg increase in body weight. A simulation showed that for typical subjects weighing 40\u201380 kg, a fixed dosage of 1500 mg daily had an area under the concentration\u2013time curve from 0 to 24 hours (AUC<jats:sub>0\u201324<\/jats:sub>) of 389.9\u2013716.0 mg\u00b7h\/L and peak serum concentrations of the drug (C<jats:sub>max<\/jats:sub>) of 32.2\u201344.8 mg\/L.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Fixed pyrazinamide doses of 1500, 1750, and 2000 mg are recommended for patients weighing 40\u201370, 70\u201380, and 80\u201390 kg, respectively, to achieve the exposure targets of AUC<jats:sub>0\u201324<\/jats:sub> &gt; 363 mg\u00b7h\/L or C<jats:sub>max<\/jats:sub> &gt; 35 mg\/L to attain efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001255","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T19:31:33Z","timestamp":1725651093000},"page":"475-483","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Modeling of Pyrazinamide Among Chinese Patients With Drug-Sensitive or Multidrug-Resistant Tuberculosis"],"prefix":"10.1097","volume":"47","author":[{"given":"Shuyan","family":"Chen","sequence":"first","affiliation":[{"name":"College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China;"},{"name":"Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiao","family":"Rao","sequence":"additional","affiliation":[{"name":"BGI-Shenzhen, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Fu","sequence":"additional","affiliation":[{"name":"Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Pulmonary Diseases Department, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiancong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong Province, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunli","family":"Liao","sequence":"additional","affiliation":[{"name":"BGI-Shenzhen, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong Province, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofang","family":"Deng","sequence":"additional","affiliation":[{"name":"Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong Province, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Lin","sequence":"additional","affiliation":[{"name":"BGI-Shenzhen, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuxin","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong Province, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Liu","sequence":"additional","affiliation":[{"name":"BGI-Shenzhen, Shenzhen, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong Province, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"R2-20250711","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS ONE"},{"key":"R4-20250711","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/AAC.20.4.556","article-title":"Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility","volume":"20","author":"McClatchy","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20250711","doi-asserted-by":"crossref","first-page":"e00070-19","DOI":"10.1128\/MMBR.00070-19","article-title":"The bewildering antitubercular action of pyrazinamide","volume":"84","author":"Lamont","year":"2020","journal-title":"Microbiol Mol Biol Rev"},{"key":"R6-20250711","first-page":"81","article-title":"The role of pyrazinamide in the chemotherapy of chronic pulmonary tuberculosis; a clinical evaluation of 39 cases treated with rotation therapy","volume":"26","author":"Calix","year":"1956","journal-title":"J Med Assoc State Ala"},{"key":"R9-20250711","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"R10-20250711","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250711","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"R12-20250711","doi-asserted-by":"crossref","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","article-title":"Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response","volume":"73","author":"Zheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R13-20250711","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R14-20250711","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)29122-4","article-title":"Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention","volume":"180","author":"Weiner","year":"1972","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20250711","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.05.00006205","article-title":"High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis","volume":"26","author":"Younossian","year":"2005","journal-title":"Eur Respir J"},{"key":"R16-20250711","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1309\/7GBYQTY62PFEHDP1","article-title":"Hyperuricemia and arthralgias during pyrazinamide therapy in patients with pulmonary tuberculosis","volume":"38","author":"Qureshi","year":"2007","journal-title":"Lab Med"},{"key":"R17-20250711","doi-asserted-by":"crossref","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS ONE"},{"key":"R18-20250711","doi-asserted-by":"crossref","first-page":"e00490-17","DOI":"10.1128\/AAC.00490-17","article-title":"Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis","volume":"61","author":"Chirehwa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250711","doi-asserted-by":"crossref","first-page":"e0187624","DOI":"10.1371\/journal.pone.0187624","article-title":"Pyrazinamide clearance is impaired among HIV\/tuberculosis patients with high levels of systemic immune activation","volume":"12","author":"Vinnard","year":"2017","journal-title":"PLoS ONE"},{"key":"R20-20250711","doi-asserted-by":"crossref","first-page":"e01978-19","DOI":"10.1128\/AAC.01978-19","article-title":"Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV","volume":"64","author":"Abdelwahab","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20250711","doi-asserted-by":"crossref","first-page":"e0081122","DOI":"10.1128\/aac.00811-22","article-title":"Population pharmacokinetic modeling of bedaquiline among multidrug-resistant pulmonary tuberculosis patients from China","volume":"66","author":"Zou","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20250711","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s13318-018-00540-w","article-title":"Population pharmacokinetic modelling of pyrazinamide and pyrazinoic acid in patients with multi-drug resistant tuberculosis","volume":"44","author":"Mugabo","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R23-20250711","doi-asserted-by":"crossref","first-page":"e0000322","DOI":"10.1128\/aac.00003-22","article-title":"Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis","volume":"66","author":"Abolhassani-Chimeh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250711","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bcp.14522","article-title":"Drug exposure of first-line anti-tuberculosis drugs in China: a prospective pharmacological cohort study","volume":"87","author":"Gao","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250711","doi-asserted-by":"crossref","first-page":"e02625-16","DOI":"10.1128\/AAC.02625-16","article-title":"Population pharmacokinetics of pyrazinamide in patients with tuberculosis","volume":"61","author":"Alsultan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250711","doi-asserted-by":"crossref","first-page":"e0004621","DOI":"10.1128\/AAC.00046-21","article-title":"Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients coinfected with HIV and implications for individualized dosing pharmacokinetics of pyrazinamide and its metabolites in patients coinfected with HIV and implications for individualized dosing","volume":"65","author":"Sundell","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250711","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1128\/AAC.00480-16","article-title":"HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients","volume":"60","author":"Rockwood","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250711","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R29-20250711","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01567-09","article-title":"Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used","volume":"54","author":"Pasipanodya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20250711","doi-asserted-by":"crossref","first-page":"e054788","DOI":"10.1136\/bmjopen-2021-054788","article-title":"Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)","volume":"12","author":"Ekqvist","year":"2022","journal-title":"BMJ Open"},{"key":"R31-20250711","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1128\/AAC.05988-11","article-title":"Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis","volume":"56","author":"Sahota","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20250711","doi-asserted-by":"crossref","first-page":"1116226","DOI":"10.3389\/fphar.2023.1116226","article-title":"Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance","volume":"14","author":"Kim","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:01:25Z","timestamp":1752235285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001255","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"2023-12-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}